HIV prevention therapy likely to become cheaper but accessibility concerns remain

Gilead Sciences collaborates with Indian companies to produce affordable generic versions of its HIV prevention therapy, lenacapavir, potentially dropping prices from $40,000 to $200-$300 annually in India. Despite the promise, experts criticize the restrictive voluntary license, which may hinder API supply and delay significant price cuts in developing countries.